ABOUT SYROSINGOPINE

Notwithstanding numerous setbacks, numerous MDM2 inhibitors have now progressed into late-phase medical progress. New strategies have also been created to boost the efficacy of MDM2 inhibitors and to mitigate their on-target toxicity. In this particular overview, we summarize the progress and problems in the development of the MDM2 specific therapy